Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

home / around-the-practice / recent-advances-in-the-treatment-of-metastatic-castration-sensitive-prostate-cancer

Expert oncologists review key studies in the m CSPC treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.

EP. 1: Case 1: Frontline Therapy in 63-Year-Old Man With High-Volume mCSPC

Neeraj Agarwal, MD;Bobby Liaw, MD;Simon Chowdhury, MD;Benjamin Lowentritt, MD

August 11th 2022

After reviewing a patient scenario of metastatic castration-sensitive prostate cancer, expert panelists break down frontline treatment options in this setting.

EP. 2: Metastatic CSPC: Is There a Continued Role for Docetaxel in the Frontline Setting?

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

August 11th 2022

Shared insight on the frontline use of chemotherapy options for patients with metastatic CSPC in the context of AR-targeted therapies.

EP. 3: Factors in Selecting Frontline Therapy for Patients With mCSPC

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

August 18th 2022

Focused discussion on drug and patient factors that aid in the selection of frontline therapy for metastatic castration-sensitive prostate cancer.

EP. 4: Toxicities and Drug-Drug Interactions With Frontline Therapies for mCSPC

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

August 18th 2022

A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.

EP. 5: Metastatic CSPC: Rationale Behind ADT + Apalutamide Therapy

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

August 24th 2022

Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.

EP. 6: Selecting Therapy for Low-Volume mCSPC

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

August 24th 2022

Panelists provide comprehensive insight on treatment strategies specific to the setting of low-volume metastatic prostate cancer.

EP. 7: Optimizing Patient Monitoring Strategies in mCSPC

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

September 1st 2022

Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.

EP. 8: Metastatic CSPC: Educating Patients on PSA Levels

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

September 1st 2022

Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.

EP. 9: Case 2: Triplet Therapy in a 59-Year-Old Man With mCSPC

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

September 8th 2022

Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.

EP. 10: Selecting Between Doublet and Triplet Therapy in mCSPC

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

September 8th 2022

Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.

EP. 11: Is There a Role for Triplet Therapy in Low-Volume mCSPC?

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

September 14th 2022

A brief discussion on the use of doublet versus triplet therapy in patients with low-volume metastatic prostate cancer.

EP. 12: Optimizing Genomic Profiling in mCSPC

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

September 15th 2022

Expert perspectives on the utilization of genomic profiling in patients with metastatic castration-sensitive prostate cancer to impact treatment decisions.

EP. 13: Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

ONCOLOGY Staff

September 18th 2022

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.

EP. 14: Metastatic CSPC: Future Directions in Care

Neeraj Agarwal, MD;Simon Chowdhury, MD;Bobby Liaw, MD;Benjamin Lowentritt, MD

September 21st 2022

Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777